LOH confers an opportunity to distinguish tumor from normal cells by targeting these genetic losses with a cellular NOT logic gate designed to mediate the attack of engineered immune cells on cancer cells that lack expression of a specific Ag, while sparing normal cells that possess the Ag (3). This evidence concerns the gene RENBP and cancer.